Surgeon, test (and heal) thyself: sharps injuries and hepatitis C risk

Katrina J R Watson

Surgeons and others who perform exposure-prone procedures are at risk of contracting blood-borne viruses, but do not always recognise or report potential exposures. They may be reluctant to report sharps injuries, or to present for testing for blood-borne virus transmission, for fear of being barred from surgical practice. Although surgeons may fear transmission of HIV in particular, it is hepatitis C that poses the greatest risk. Estimates of this risk have sometimes included an alarmingly high predicted cumulative incidence of hepatitis C. However, cross-sectional studies show the actual seroprevalences of hepatitis C in surgeons to be equivalent to, or slightly higher than, those of the general population. Therefore, the risk seems to be considerably lower than might be predicted, and can be estimated by the formula in Box 1.

From this formula, a surgeon who performs 300 procedures per year and is at the end of a 35-year surgical career has a risk of 4.9% of being HCV antibody-positive, with a 3.8% risk of being RNA-positive on polymerase chain reaction testing (people are not infectious and will not develop any disease unless they are HCV RNA-positive). The lower and upper bounds of being RNA-positive using the highest published estimates of Pr(si) and Pr(trans) are 3.2% and 26.3%. The estimated prevalence of RNA positivity (using the most commonly accepted average probabilities) after 15 years of surgical practice (ie, mid-career) is 1.6% (equivalent to the general population).

Risks to patients from HCV-positive surgeons

Surgeons who are HCV-positive pose a low, but definite potential, risk to patients. As acute hepatitis C is usually asymptomatic, infection will often be unrecognised. Although several published cases have documented surgeon-to-patient transmission, the investigations that have followed such cases have generally shown no or minimal exposure in other patients of these surgeons — transmission rates of 0.036%–2.2%. An estimate of risk to an individual patient from a surgeon known to be HCV antibody-positive is shown in Box 2.

The overall probability of transmission in such a situation is 0.0001 (or 1 per 10 000 procedures). This is somewhat lower than some published estimates, which have used higher probabilities for some variables.

Risks to patients during the “window period” of infection

If a surgeon sustains a known sharps injury from an RNA-positive patient, protocols for testing vary. A recommended protocol is RNA testing at 4 weeks, followed by anti-HCV testing at 8 and 12 weeks. Tests for RNA usually become positive between 10 days and 6 weeks after infection. The risk that a surgeon might transmit hepatitis C during this window period is derived by multiplying the formula in Box 2 by the transmission risk to surgeon (1.8%), so that the overall risk to an individual patient is 0.000002, or 2 per million procedures.

Treatment for people who acquire hepatitis C through surgery

The major advantage of early testing is access for the surgeon to probable cure. Jaeckel et al showed that, of 44 German patients treated with high-dose interferon monotherapy, 99.5% achieved a cure. There was no control group, and historical data were used. These patients differed from the situation in exposed surgeons, as almost all patients were symptomatic. However, the distribution of genotypes was similar to that in Australia. Most patients (61%) had type 1 (the more “difficult to treat” genotype). The patients received 5 million units of interferon alfa-2b subcutaneously daily for 4 weeks, followed by 5 million units three times a week for another 20 weeks. Despite these relatively high doses, there were no serious adverse effects. Only one patient withdrew (at 12 weeks, because of hair loss and flu-like symptoms).

A recent German–Egyptian study indicates that pegylated interferon combined with ribavirin can achieve results similar to those with high-dose interferon. This treatment has fewer adverse effects than non-pegylated interferon. Sustained virological response was a little lower than in the Jaeckel study (85% for combination pegylated interferon–ribavirin, and 80% for pegylated interferon monotherapy). This may be because treatment was not commenced until 16 weeks after HCV infection, compared with a mean of 89 days in the Jaeckel study. Some
people advocate a similar strategy (ie, waiting for 3, or even 4, months) in all acutely infected individuals, as up to 30% of people clear the virus spontaneously. However, this extra time may affect treatment outcome adversely. Moreover, in the case of surgeons, this would necessitate an additional 2–3 months during which the surgeon would be known to be RNA-positive (at 4 weeks after exposure), but would be unable to operate.

**Regular scheduled testing in surgeons**

Testing after known sharps injuries will not detect all exposure in surgeons, because some injuries are not recognised, and hepatitis C is usually asymptomatic. Thus, regular testing for surgeons may be prudent to offer them relatively early treatment, and a better prospect of cure. Treatment for chronic hepatitis C has a 50% (range, 40%–85%) cure rate, but earlier detection of hepatitis C (ie, within 12 months of infection) allows a greater chance of cure, somewhere between 50% (cure rate for chronic infection) and 99% (cure rate for early acute infection).

**Conclusion**

In summary, it is time to ensure that surgeons are aware of the compelling reasons to be tested for HCV, both after exposure and on a regular basis. The evidence shows that surgeons should not be barred from operating while waiting for an HCV RNA result after known exposure to patients positive for HCV RNA, as the risk of transmission is extremely low. However, surgeons who are known to be HCV RNA-positive should not perform exposure-prone procedures (procedures where the hands are in a body cavity with sharp instruments but limited visibility) until after successful treatment (ie, RNA-PCR testing negative repeatedly 6 months after treatment). Surgeons should be reassured that early detection of HCV is associated with an extremely high chance of a cure with prompt treatment.

**Competing interests**

The author has attended, organised and spoken at scientific meetings sponsored in whole or part by various companies that produce diagnostic tests or antiviral treatments for hepatitis C. The author has also been an investigator in clinical trials of antiviral agents sponsored by pharmaceutical companies.

**References**

6 Battey RG. Hepatitis C: where are we at and where are we going? Med J Aust 2002; 176: 361-362.